Cita APA (7a ed.)
Günaltılı, M., Bölek, H., Kaplan Tüzün, E., Usta, S., Efil, S. C., Akkus, A. F., . . . Yekedüz, E. (2026). Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study. Cancers, 18(13), 2127-2141.
Cita Chicago Style (17a ed.)
Günaltılı, Murat, et al. "Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study." Cancers 18, no. 13 (2026): 2127-2141.
Cita MLA (9a ed.)
Günaltılı, Murat, et al. "Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study." Cancers, vol. 18, no. 13, 2026, pp. 2127-2141.
Precaución: Estas citas no son 100% exactas.